Diamyd Medical AB (FRA:DMN) PS Ratio: (As of Aug. 10, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:DMN Diamyd Medical AB FRA:DMN
41 GF Score
Price €0.07
GF Value €0.07
Valuation Fairly Valued
! 3 Warning Signs
View Full Analysis

What is Diamyd Medical AB PS Ratio?

The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, Diamyd Medical AB's share price is €0.0725. Diamyd Medical AB's Revenue per Share for the trailing twelve months (TTM) ended in May. 2026 was €0.00. Hence, Diamyd Medical AB's PS Ratio for today is .

Good Sign:

Diamyd Medical AB stock PS Ratio (=336.67) is close to 5-year low of 336.67.

The historical rank and industry rank for Diamyd Medical AB's PS Ratio or its related term are showing as below:

FRA:DMN' s PS Ratio Range Over the Past 10 Years
Min: 113.9   Med: 1410.22   Max: 18075.74
Current: 336.67

During the past 13 years, Diamyd Medical AB's highest PS Ratio was 18075.74. The lowest was 113.90. And the median was 1410.22.

FRA:DMN's PS Ratio is ranked worse than
92.37% of 930 companies
in the Biotechnology industry
Industry Median: 9.51 vs FRA:DMN: 336.67

Diamyd Medical AB's Revenue per Sharefor the three months ended in May. 2026 was €0.00. Its Revenue per Share for the trailing twelve months (TTM) ended in May. 2026 was €0.00.

Warning Sign:

Diamyd Medical AB revenue per share has been in decline for the last 5 years.

During the past 12 months, the average Revenue per Share Growth Rate of Diamyd Medical AB was 200.00% per year. During the past 3 years, the average Revenue per Share Growth Rate was -45.00% per year. During the past 5 years, the average Revenue per Share Growth Rate was -29.10% per year. During the past 10 years, the average Revenue per Share Growth Rate was -27.20% per year.

During the past 13 years, Diamyd Medical AB's highest 3-Year average Revenue per Share Growth Rate was 63.00% per year. The lowest was -87.30% per year. And the median was -32.50% per year.

Back to Basics: PS Ratio


Diamyd Medical AB  (FRA:DMN) PS Ratio Explanation

The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.

When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.

Similar to the PE Ratio or Price-to-Operating-Cash-Flow or Price-to-Free-Cash-Flow , the PS Ratio measures the valuation based on the earning power of the company. This is where it is different from the PB Ratio , which measures the valuation based on the company's balance sheet.


Be Aware

The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.


Diamyd Medical AB PS Ratio Related Terms


Diamyd Medical AB PS Ratio Historical Data

* Premium members only.

The historical data trend for Diamyd Medical AB's PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Diamyd Medical AB PS Ratio Chart

Diamyd Medical AB Annual Data
Trend Aug16 Aug17 Aug18 Aug19 Aug20 Aug21 Aug22 Aug23 Aug24 Aug25
PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 8,187.57 2,361.52 1,392.08 0.00 0.00

Diamyd Medical AB Quarterly Data
Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23 Aug23 Nov23 Feb24 May24 Aug24 Nov24 Feb25 May25 Aug25 Nov25 Feb26 May26
PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 3,460.00 4,946.67 372.67

FRA:DMN vs VRTX, REGN, RVMD: PS Ratio Comparison

For the Biotechnology subindustry, Diamyd Medical AB's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Diamyd Medical AB PS Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Diamyd Medical AB's PS Ratio distribution charts can be found below:

* The bar in red indicates where Diamyd Medical AB's PS Ratio falls into.


FRA:DMN
41GF Score
Diamyd Medical AB FRA:DMN
PS Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Diamyd Medical AB PS Ratio Calculation

The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.

Diamyd Medical AB's PS Ratio for today is calculated as

PS Ratio=Share Price/Revenue per Share (TTM)
=0.0725/0
=

Diamyd Medical AB's Share Price of today is €0.0725.
Diamyd Medical AB's Revenue per Share for the trailing twelve months (TTM) ended in May. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.00.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

PS Ratio=Market Cap/Revenue

The Revenue here is for the trailing 12 months.

Is Diamyd Medical AB (FRA:DMN) Overvalued in 2026?

Based on GuruFocus' analysis, Diamyd Medical AB stock appears to be overvalued. The current stock price of €0.07 is trading 3.6% above its estimated GF Value™ of €0.07. GuruFocus considers Diamyd Medical AB to be Fairly Valued.

Key valuation signals for FRA:DMN:

  • PS Ratio:
  • GF Value™: €0.07 vs. price of €0.07 (3.6% above fair value)
  • GF Score™: 41/100 with 3 warning signs

No single metric tells the full story. See the FRA:DMN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Diamyd Medical AB Business Description

Other Exchanges DMYD B:Sweden
Address Kungsgatan 29, Stockholm, SWE, SE-111 56
Diamyd Medical AB develops precision medicine therapies for the prevention and treatment of type 1 diabetes using antigen-based immune technology. Its product candidate, Diamyd (rhGAD65/alum), is an antigen-specific immunomodulatory therapy that aims to preserve endogenous insulin production in individuals carrying the HLA DR3-DQ2 genotype and is being evaluated in the registrational Phase 3 DIAGNODE-3 trial in Stage 3 type 1 diabetes, as well as in the DiaPrecise trial in children with Stage 1 and Stage 2 type 1 diabetes. The Company's activities include clinical development, antigen-specific immunotherapy and in-house manufacturing of recombinant GAD65.
41GF Score

Get the complete analysis for FRA:DMN

PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.07
Price
€0.07
GF Value